A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 135-136

Informa Healthcare

Access to resources Recommend Favorite

Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

By Rocchi A.   Verma S.  

Supportive Care in Cancer, Vol. 14, Iss. 9, 2006-09 ,pp. : 917-927

Springer Publishing Company

Access to resources Recommend Favorite

Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

By Cella David   Fallowfield Lesley   Barker Peter   Cuzick Jack   Locker Gershon   Howell Anthony  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 273-284

Springer Publishing Company

Access to resources Recommend Favorite

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

By Skedgel C.   Rayson D.   Dewar R.   Younis T.  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 325-333

Springer Publishing Company

Access to resources Recommend Favorite

Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer

By Ouagari Khalid   Karnon Jon   Delea Thomas   Talbot Willena   Brandman Jane  

Breast Cancer Research and Treatment, Vol. 101, Iss. 1, 2007-01 ,pp. : 37-49

Springer Publishing Company

Access to resources Recommend Favorite